Brandywine Pharmaceuticals Recalls Theophylline Tablets Over Stability Testing Deviations
Brandywine Pharmaceuticals is recalling two lots of prescription Theophylline Extended-Release Tablets nationwide due to manufacturing deviations.
Brandywine Pharmaceuticals, LLC has recalled prescription Theophylline Extended-Release Tablets in 100 mg and 200 mg strengths. The nationwide recall applies to 100-count bottles distributed across the United States.
The recall was initiated due to current good manufacturing practice (CGMP) deviations involving an interruption in the ongoing stability testing program conducted at a third-party laboratory.
The recall affects 1,620 bottles of the 100 mg tablets and 1,332 bottles of the 200 mg tablets. The U.S. Food and Drug Administration has classified this action as a Class II recall.
What to do
- Stop using the recalled prescription product.
- Consult your physician or healthcare provider regarding alternative treatment options.
- Contact Brandywine Pharmaceuticals, LLC or the FDA for additional information.
At a glance
| Agency | U.S. Food and Drug Administration (FDA) |
|---|---|
| Recall numbers | D-0110-2027, D-0111-2027 |
| Date | 2026-11-04 |
| Company | Brandywine Pharmaceuticals, LLC, West Chester, PA |
| Severity | Class II |
| Quantity | 1,620 100-count bottles; 1,332 100-count bottles |
| Where sold | Nationwide within U.S |
| Lot codes / identifiers | Lot: 405617, Expiry: 03/31/2028; Lot: 405620, Expiry: 03/31/2028. |
Recalled products
- Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
- Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.
Source: official FDA notice. This summary was written by 365 News from the official notice. Details can change; check the notice before acting.